about
Gemcitabine-based chemotherapy for advanced biliary tract carcinomasMicroRNA aberrations: An emerging field for gallbladder cancer managementGallbladder Cancer in the 21st Century.Conversion of laparoscopic cholecystectomy to open surgical procedure due to complete fibrosis of the gallbladderAdjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base.Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κBAnalysis of prognostic factors for survival after surgery for gallbladder cancer based on a Bayesian network.Long non-coding RNA expression profiles in gallbladder carcinoma identified using microarray analysis.Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Dioscin Induces Gallbladder Cancer Apoptosis by Inhibiting ROS-Mediated PI3K/AKT SignallingDifferential expression of cholecystokinin A receptor in gallbladder cancer in the young and elderly suggests two subsets of the same disease?Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancerSuccessful curative resection of gallbladder cancer following S-1 chemotherapy: A case report and review of the literature.Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5pDifferentiation therapy: sesamin as an effective agent in targeting cancer stem-like side population cells of human gallbladder carcinomaGall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread.Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeuticsSurgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer.Diagnosis and management of gallbladder cancer.Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.Upregulation of H19 indicates a poor prognosis in gallbladder carcinoma and promotes epithelial-mesenchymal transition.Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsRescued expression of WIF-1 in gallbladder cancer inhibits tumor growth and induces tumor cell apoptosis with altered expression of proteins.AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer.Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy ConsortiumUpregulation of long non-coding RNA LINC00152 by SP1 contributes to gallbladder cancer cell growth and tumor metastasis via PI3K/AKT pathway.Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9.Establishment and characterization of a novel highly aggressive gallbladder cancer cell line, TJ-GBC2.Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1α via miR-138.A case report of the clear cell variant of gallbladder carcinoma.Synchronous extraskeletal Ewing's sarcoma/PNET and gallbladder carcinoma: a case report and literature review.Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling.
P2860
Q24187573-BCF14BC6-ED0F-491C-8417-B7CA5F02FBF2Q26768416-3F89A14E-D803-4874-809E-E3FAE86895E6Q26784174-6B23A5AC-B149-47DA-921B-238A5505DBA6Q30411135-8FA6FC78-E3D7-418B-BA69-C4BAC836847DQ31135072-A87FAB6F-7628-4E59-8624-C7D028F82A22Q33572367-189C9DE8-89C5-49C7-B3D6-5D205EB0D7EBQ33672198-0143A910-21EB-43B1-A587-D1E119A51D16Q33686002-47D81352-6EF0-475C-853E-A2652EE4E757Q33686177-29A05BCC-BF1C-4C37-877E-5B6801D0926FQ33688577-9E8EC208-8671-46AA-9117-EE16D4E10B93Q33723528-19C0F7E6-1C4C-4A2A-90AB-CF9B4FDE4F6DQ33837280-FBBD85AB-073E-4537-8B8F-76226524C86AQ33849781-87B32F9C-3111-451A-BBC3-803154A8C5D1Q33858811-E145DEAD-B1BF-46B1-860E-98EC08553A2CQ34427188-17F37ED5-E7EA-4375-881E-2C26A2D51178Q34457236-54F03476-ECC4-4671-8FF4-BB72799A4935Q34467897-5A493FC6-9AA8-4AF5-9D4C-156D187E7FBBQ35179333-453996B9-3F56-4591-9EDC-EE11B419D187Q35406568-89EC9710-2226-4785-A0C9-08110EF7AF8AQ36072795-A903BBD9-EDF5-45E8-A3E2-01CC746CF1BCQ36132324-29E4453A-BFFF-47F1-972B-70576157336BQ36179711-B44B65F2-8DC8-4F8A-89C7-9E92CAF1E051Q36278688-CE1A6EE4-CBD1-49E9-81A9-F7FEAE127E4AQ36424359-AE77D547-32FC-480A-840F-3E3C2A91211BQ36595032-7919E61B-2B7C-448B-8AC4-1531D670D2CFQ36984860-F97F0C1A-BDDC-45F2-A001-14A154FBA604Q37190811-CAF0E9D7-5684-4BE7-8221-C57BF09F28C7Q37225342-58278369-7C7D-4E18-ABE6-CCF181A21DF4Q37307816-49F86E0F-C3E0-41DE-94CB-961CF23B604AQ37391705-E0E8494D-C1B8-4779-8497-77E5136AB2EDQ37393385-90DA2287-F70B-4DA9-AB8D-8AD602109B6FQ37437323-CE47D753-F036-401F-920B-D3C3C14EB701Q37452157-663AC683-08BA-4135-84D5-D3AC3022FFFEQ37633684-3E8B3BFA-94ED-4C31-90FA-FC37184EC65FQ37637102-55A10EEB-DAC9-4041-B294-277589B132BBQ37653477-1627C37B-F238-47FD-885F-087D2E90A2D7Q37657695-E9666539-1ED5-4B2E-9093-1A011359DBE5Q37692140-99A74B3B-0D3D-4F84-BC15-A32856D528FDQ37706353-330A6FB0-7DCF-4E7F-8C09-BFCFEBCB4F81Q37746213-31508618-9751-45C2-BC73-A31AFDD0182A
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Current management of gallbladder carcinoma.
@ast
Current management of gallbladder carcinoma.
@en
type
label
Current management of gallbladder carcinoma.
@ast
Current management of gallbladder carcinoma.
@en
prefLabel
Current management of gallbladder carcinoma.
@ast
Current management of gallbladder carcinoma.
@en
P2093
P2860
P1433
P1476
Current management of gallbladder carcinoma.
@en
P2093
Andrew X Zhu
Aram F Hezel
David A Kooby
Theodore S Hong
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0302
P577
2010-02-10T00:00:00Z